Skip to main content
INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD. logo

INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688253 ISIN · CNE100005Q14 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 480 across all filing types
Latest filing 2026-05-21 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688253

About INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD.

https://www.innovitaivd.com/

INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD. specializes in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical instruments. The company’s core business activities center on providing rapid diagnostic solutions across multiple clinical fields, including respiratory health, infectious diseases, fertility, and chronic disease management. Its technical platforms encompass lateral flow immunoassay, fluorescence immunoassay, and molecular diagnostics. Key products include point-of-care testing (POCT) kits for pathogens such as Influenza A/B, Respiratory Syncytial Virus (RSV), and SARS-CoV-2. Innovita serves a global market of hospitals, clinical laboratories, and public health organizations, focusing on delivering high-sensitivity diagnostic tools that facilitate early detection and informed clinical decision-making.

Recent filings

Filing Released Lang Actions
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the company’s 2025 Annual General Meeting, including detailed voting results for each proposal, attendance, and meeting procedure confirmations. This matches the category for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-21 Chinese
关于变更保荐代表人的公告
Regulatory Filings Classification · 85% confidence The document is an official announcement by Beijing Innote Biotech regarding the change of its IPO sponsorship representative. It does not contain financial statements, governance policies, or board member appointments—it is a compliance/regulatory notice about sponsor rep changes related to the company’s listing oversight. This falls under the generic Regulatory Filings category (RNS).
2026-05-11 Chinese
2025年年度股东会会议资料
AGM Information Classification · 99% confidence The document is titled “2025年年度股东会会议资料” (2025 Annual General Meeting Materials) and contains the meeting notice, agenda, proposals, and attachments prepared for the annual shareholders’ meeting. It is the material distributed to shareholders in advance of the AGM, fitting the definition of AGM Information.
2026-05-11 Chinese
关于变更注册资本、修订《公司章程》并办理工商登记的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Beijing Innotech Biotechnology Co., Ltd. regarding changes in registered capital and amendments to the company's articles of association. It details the board meeting resolutions and the proposed changes to the company's capital and articles, and mentions that these changes will be submitted for shareholder approval and subsequent registration. The document is a formal announcement of corporate governance and capital structure changes, not a full report or financial statement. It is not an annual or interim report, nor a detailed management discussion or earnings release. It fits the category of Share Issue/Capital Change (SHA) because it involves changes in registered capital and related corporate governance documents.
2026-04-27 Chinese
2025年度会计师事务所的履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (auditor) for the fiscal year 2025. It details the auditor's qualifications, quality management, work plan, resources, and risk management related to the audit of the company's 2025 annual report. It is not the annual report itself, nor is it a certification or a brief announcement. It is a standalone audit-related report assessing the auditor's performance and compliance with regulatory requirements. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and related information excluding the full annual report. The document length is 2448 characters, which is consistent with a detailed audit evaluation report rather than a short announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2025
2026-04-27 Chinese
2025年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' (Audit Report) and is issued by a certified public accounting firm (大信会计师事务所). It contains detailed audit opinions, basis for audit opinions, key audit matters such as revenue recognition and R&D expenses, responsibilities of management and auditors, and includes full financial statements such as consolidated and parent company balance sheets and income statements for the fiscal year ending December 31, 2025. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content matches the characteristics of a standalone audit report rather than a full annual report (10-K) because it focuses on the audit opinion and audit procedures rather than comprehensive company activities or management discussion. Therefore, the document is best classified as an Audit Report / Information (AR). FY 2025
2026-04-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.